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FORMULATIONS AND METHODS TO 
TREAT AND PREVENT EQUINE 
PROTOZOAL MYELOENCEPHALITIS 
BACKGROUND OF THE INVENTION 
Equine ProtoZoal Myeloencephalitis (EPM) is the leading 
infectious neurologic disease of American horses. Consis 
tently safe and effective treatments for this disease are not 
available. Conventional therapy relies on relatively non 
speci?c drug/medication combinations; these approaches 
are only partially effective and relapses and/or adverse 
reactions are common. 
EPM is a NeW World disease and is the most common 
infectious neurological disease of horses in the Western 
hemisphere. It is caused by an “apicomplexan” parasite 
called Sarcocystis neurona (S. HQZU‘OI’LLZ), Which cycles natu 
rally betWeen opossums and birds. The horse is an aberrant 
host, becoming exposed When it consumes infectious mate 
rial from opossum feces. In the horse, S. neurona makes its 
Way to the brain and spinal cord, Where it proliferates and 
causes clinical disease. 
The epidemiology and economic signi?cance of S. neu 
rona infection is substantial. In endemic areas in the U.S., 
over 40% of horses are seropositive. Of these, a small 
percentage are clinically affected. Of animals clinically 
affected, 30—40% reportedly fail to respond to current 
therapy, and some of these animals die. Better and more 
effective prophylactic and therapeutic modalities are 
required. 
The economic loss in performance horse breeding is 
likely more substantial than the above ?gures suggest. The 
?gures presented refer to clinically observable infections 
only. Subclinical infections Will shoW only at the racetrack, 
Where Well-bred animals may fail to perform to their genetic 
potential because of subclinical infection With EPM. While 
unrecorded, these losses may be signi?cant. 
EPM occurs Wherever opossums are found. All cases of 
EPM therefore trace to Western hemisphere exposure, and 
the incidence of EPM is likely greatest in areas With high 
opossum populations. HoWever, clinical cases of EPM are 
found throughout the World, because horses Who become 
infected With S. neurona While in opossum territories may be 
transported elseWhere. 
The localiZation of S. neurona in the brain and spinal cord 
is a critical obstacle to treatment of EPM. The brain and 
spinal cord are immunologically privileged; as such, 
immune responses are likely less effective in the brain than 
elseWhere. Current treatments, as detailed beloW, do not 
directly kill S. 11614701161,‘ as such they often fail to effect a 
“cure.” The present treatment method directly kills S. 
11614701161, making it dramatically different from previous 
treatments. 
Previous therapy for BPM consists of administration of 
various combinations of sulfonamides, trimethoprim and 
pyrimethamine (Daraprim). HoWever, many horses relapse 
When therapy ceases, probably because the current therapies 
do not cross the blood/brain barrier reliably and/or attack the 
organism directly. These agents only hinder proliferation of 
S. neurona and do not kill it. The inability of current 
treatments to kill S. neurona likely contributes to the sig 
ni?cant relapse rate after therapy ceases. 
One of the major concerns about current therapeutic 
approaches to EPM is the difficulty in maintaining simulta 
neous minimum inhibitory concentrations (MICs) of 
pyrimethamine, trimethoprim and sulfonamides in the CNS. 
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2 
Because of the uncertainty of the oral bioavailability and 
steady state concentrations of these agents in the CNS, and 
the fact that other treatment regimens may be only 
apicomplexistatic, the availability of a highly lipid-soluble 
agent With a long plasma half-life, good CNS entry 
characteristics, and the ability to kill S. neurona in the CNS 
Would be a useful addition to the anti-EPM therapeutic 
armamentarium. Additionally, current therapeutic 
approaches are associated With signi?cant adverse responses 
in treated animals, one of Which is dysbacteriosis resulting 
in lethal diarrhea and anemia. Amore effective and less toxic 
agent Would be highly desirable. The present invention 
provides these features, Whereas the previous treatments do 
not 
The present treatment methods utiliZe triaZine-based 
anticoccidials, preferably diclaZuril, to prevent and treat 
EPM, Without the side effects of previous EPM treatments. 
EPM and coccidiosis are both caused by “apicomplexan” 
parasites; hoWever, coccidiosus does not affect the CNS as 
does EPM. 
TriaZine-based compounds have previously been used in 
the prophylaxis of coccidiosis in poultry in Canada, Europe, 
and South America. Vanparijs et. al., 129 Vet. Rec. 339 
(1991); Driessen et. al., 72Aust. Vet. 139 (1995). DiclaZuril 
has been used to treat coccidiosus in turkeys, ducks, quail, 
guinea-foWl, pheasants, partridges, mice, rats, dogs, rabbits, 
cattle, and horses. Lindsay et al., 55 Am. J. Vet. Res. 976 
(1994); Lindsay et al., 81(2) J. Parisitol. 315 (1995); and 
Vanparijs et al., 32 Vet. Parisitol. 109 (1989). US. Pat. No. 
4,952,570 also discloses the use of triaZine-based com 
pounds (including diclaZuril) to treat protoZoal infections, 
although neither Equine ProtoZoal Myelitis nor S. neurona 
are mentioned. Moreover, diclaZuril, in particular is gener 
ally considered non-absorbable by the small intestine, and 
systemic treatment of protoZoal infections not possible. 
DiclaZuril has been shoWn to be active against Neospora 
caninum, another apicomplexan organism, in vitro but not 
yet in vivo. Lindsay et. al., 55 Amer. V et. J. R. 926 (1994) 
and Dubey and Lindsay, 67 Vet. Parisitol. 1 (1996). Dicla 
Zuril has also been shoWn to be effective against intestinal 
Eimeria spp. in many avian hosts and against intestinal and 
hepatic coccidiosis in rabbits. Vanparijs et. al., 32 Vet. 
Parisitol. 109 (1989). 
In other Work, diclaZuril has been used in the prophylaxis 
and treatment of experimental T gondii infection in mice. 
While diclaZuril alone or in combination With 
pyrimethamine protected mice against death folloWing 
inoculation With T gondii, diclaZuril, alone or in combina 
tion did not prevent tissue cyst formation, including brain 
tissue cyst formation in surviving mice. Based on this Work 
in mice, Lindsay concluded that combinations of diclaZuril 
and pyrimethamine may be bene?cial in the treatment of 
toxoplasmosis in man and animals Lindsay et. al., 81(2) J. 
Parisitol. 315 (1995). More importantly, the mice in these 
experiments died from pneumonia and hepatitis; there is no 
evidence from the Lindsay experiments to suggest that 
diclaZuril is effective in the treatment of encephalitis. The 
data shoW that diclaZuril did not prevent tissue cyst forma 
tion in the CNS. 
SUMMARY OF THE INVENTION 
It is therefore an object of the present invention to provide 
formulations and methods to prevent or treat EPM compris 
ing administering a pharmaceutically acceptable amount of 
a triaZine-based anti-coccidial such as claZuril, diclaZuril, 
toltraZuril or letraZuril. Treatments and formulations Which 
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include a combination of other therapies With the presently 
disclosed therapy for treatment of active infection are also 
Within the scope of the present invention. 
De?nitions: 
“EPM” means equine protoZoal myelitis or equine pro 
toZoal myeloencephalitis or a disease Which manifests as 
symptoms of either equine protoZoal myelitis or equine 
protoZoal myeloencephalitis, or closely related 
apicomplexan-based neurological diseases of horses. 
DETAILED DESCRIPTION OF THE 
INVENTION 
The present invention provides formulations of triaZine 
based anticoccidials for the use in preventing and/or treating 
EPM. For preventative therapy, a horse-feed based formu 
lation is preferred. Most preferred is a horse-feed formula 
tion Which comprises diclaZuril. For treatment of clinical or 
sub-clinical EPM, an oral formulation is preferred. A most 
preferred oral formulation is one Which is administered as a 
paste. Speci?cally, an oral formulation Which comprises a 
triaZine-based anticoccidial, is administered as a paste, and 
further comprises other desirable therapeutics, such as anti 
in?ammatories, sulfonamides, trimethoprim, 
pyrimethamine and/or other anti-protoZoals is considered 
Within the scope of the present invention. 
The present invention also provides methods to treat EPM 
in a horse in need of such treatment, comprising adminis 
tering a pharmaceutically acceptable amount of a triaZine 
based anti-coccidial. Preferred is a method to treat EPM 
using claZuril, diclaZuril, toltraZuril or letraZuril. Most pre 
ferred is a method to treat EPM using toltraZuril or dicla 
Zuril. Also preferred is a method to treat EPM using a 
triaZine-based anti-coccidial in combination With an anti 
in?ammatory agent and/or previously-knoWn treatment 
modalities. 
Moreover, since horses are a dead-end host for S. 
11614701161, triaZine-based anticoccidials may be administered 
prophylactically to horses likely to come in contact With the 
organism, Without the risk of producing a triaZine-based 
anti-coccidial-resistant S. neurona in the environment. 
Therefore, the present invention also provides methods to 
prevent S. neurona infection in horses comprising adminis 
tering a prophylactic amount of a triaZine-based anticoc 
cidial. Preferred is a method to prevent S. neurona infection 
by administering claZuril, diclaZuril, toltraZuril or letraZuril. 
Most preferred is a method to prevent S. neurona infection 
using toltraZuril or diclaZuril. 
The treatments provided are able to completely kill all S. 
neurona present in the animal. Aconsiderable portion of the 
recovery from the clinical symptoms of infection, hoWever, 
occurs after treatment, because clearance of dead S. neurona 
organisms, reduction of in?ammatory response and repair of 
damaged neurons normally takes up to a year. Exercise and 
anti-in?ammatory medication play a positive role in the 
repair process. 
In order to diagnose a horse With clinical EPM, it should 
be both CSF positive for S. neurona antibodies and shoW a 
history and clinical signs consistent With EPM. Other non 
S. neuronal-based causes of neuropathy must also be 
excluded. Afurther sign is response and/or relapse folloWing 
standard therapy, if the information is available. 
The folloWing is provided as a guideline for diagnosing 
EPM, although those in the art are familiar With differential 
diagnosis techniques. Moreover, treatment of mis-diagnosed 
horses pursuant to the present methods Would not result in 
resistant S. neurona for reasons previously discussed. A 
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horse With EPM tends to shoW the folloWing clinical/clinical 
chemistry signs: 
The horse Will: be grade 3—4 on a ?ve point scale 
neurological exam; asymmetric in muscle vitality; positive 
for EPM on spinal tap by Western blot, have exhibited 
relapse after current treatment, With all other potential 
causes of ataxia excluded. 
The triaZine-based anticoccidials can be purchased from 
commercial sources, such as Janssen Pharmaceutica in Bel 
gium (claZuril, letraZuril and diclaZuril) or Bayer AG in 
Leverkusen, Germany (toltraZuril). HoWever, one skilled in 
the art is aWare hoW to synthesiZe these compounds de novo 
using conventional methods. 
Formulations can be made using conventional formula 
tion technology. Horse food composition is Well knoWn in 
the art. The present formulation comprises adding at least 
one triaZine-based anti-coccidial to the feed as it is made or 
after it is made, so as to provide an overall composition 
consistent With the dosages necessary for prophylaxis or 
treatment, depending on the use. For instance, for a feed 
Which Would be useful as a prophylactic treatment, the 
folloWing formulation could be made (all percentages are by 
Weight, not less than the numbers given): 
Diclazuril 0.0002—0.002% 
protein 10% 
fat 3.5% 
?ber 6.0% 
calcium 0.6% 
phosphorus 0.45% 
copper 35 ppm 
Zinc 140 ppm 
selenium 0.6 ppm 
vitamin A 3,000 IU/lb 
A feed Which Would be useful as a treatment of clinical 
EPM, could have the folloWing composition, for instance: 
Toltrazuril 0.1—0.5% 
protein 10% 
fat 3.5% 
?ber 6.0% 
calcium 0.6% 
phosphorus 0.45% 
copper 35 ppm 
Zinc 140 ppm 
selenium 0.6 ppm 
vitamin A 3,000 IU/lb 
HoWever, a preferred embodiment of a feed formulation for 
treating EPM Would be: 
Diclazuril 0. 25 % 
protein 10% 
fat 3.5% 
?ber 6.0% 
calcium 0.6% 
phosphorus 0.45% 
copper 35 ppm 
Zinc 140 ppm 
selenium 0.6 ppm 
vitamin A 3,000 IU/lb 
Simple oral formulations may also be made using avail 
able Clinacox, oats and molasses, or Clinacox, oats, sWeet 
feed, bran and Water, for example. Moreover, any formula 
tion Which comprises a triaZine-based anti-coccidial and 
prior EPM treatment methods is considered Within the scope 
of the present invention. For example, sulfonamides, trime 
5,883,095 
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thoprim and pyrimethamine (Daraprim) added to the above 
formulations are Within the purview of the present invention. 
Of course, the formulation Would have to be adjusted for the 
appropriate pharmaceutically-acceptable percentage of ?nal 
concentration of all ingredients. 
Moreover, since paste formulations are the generally 
preferred mode of administration of orally-bioavailable 
compounds, a paste formulation acceptable to horses is 
hereby provided. Any carriers or excipients, preferably those 
Which enhance absorption, can also be included in the 
present formulations. One such absorption-enhancing car 
rier is lactose. Other carriers knoWn in the art may also be 
used. SWeetners or other ?avor-enhancers may be used as 
Well. 
Some examples of suitable carriers, excipients and dilu 
ents include lactose, dextrose, sucrose, sorbitol, mannitol, 
starches, gum acacia, calcium phosphate, alginates, 
tragacanth, gelatin, calcium silicate, microcrystalline 
cellulose, polyvinylpyrrolidone, cellulose, Water syrup, 
methyl cellulose, methyl-and propylhydroxybenZoates, talc, 
magnesium stearate and mineral oil. The formulations can 
additionally include lubricating agents, Wetting agents, 
emulsifying and suspending agents, preserving agents, 
sWeetening agents or ?avoring agents. The formulations 
may be made so as to provide quick, sustained or delayed 
release of the active ingredient after administration to the 
patient by employing procedures Well knoWn in the art. 
The formulations are preferably formulated in a unit 
dosage form, each dosage containing from about 0.1 to 10% 
active ingredient by Weight, more usually about 0.25 to 5% 
of the active ingredient. The term “unit dosage form” refers 
to physically discrete unites suitable as unitary dosages for 
mammals, each unit containing a predetermined quantity of 
active material calculated to produce the desired therapeutic 
effect, in association With a suitable pharmaceutical carrier. 
Formulations of the present invention could therefore also 
contain acceptable amounts of the folloWing ingredients: 
grain products, molasses products, plant protein products, 
soybean oil, calcium carbonate, salt, attapulgite clay, dical 
cium phosphate, sodium selenite, propionic acid, choline 
chloride, tetrasodium pyrophosphate, calcium pantothenate, 
vitamin E supplement, ribo?avin supplement, vitamin B-12 
supplement, niacin supplement, vitamin A supplement, vita 
min D-3 supplement, ferrous carbonate, manganous oxide, 
Zinc oxide, copper sulfate, magnesium oxide, calcium iodate 
and cobalt carbonate. 
These compounds may be administered in any formula 
tion Which alloWs EPM to be treated. For feed formulations, 
it is important to give enough feed to the animal to ensure 
ingestion of the required dose. For example, it is necessary 
to take into account Wasted feed that is left in the feeding 
area and inaccessible to the animal. Moreover, the com 
pounds and/or formulations may be administered via any 
acceptable method or route. For example, the compounds 
and/or formulations may be administered in the feed, 
through formulation With the feed, or via liquid or solid (ie. 
poWder) added at the time of feeding. The compounds 
and/or formulations can also be administered intravenously, 
transdermally, sublingually, transmucosally, via tablet, pill, 
poWder, loZenge, sachet, cachet, elixir, suspension, 
emulsion, solution, syrup, aerosol (as a solid or in a liquid 
medium), ointment, soft or hard gelatin capsule, suppository, 
sterile injectable solution, sterile packaged poWder and 
transdermal patch. 
The dosage for treatment of EPM Will preferably vary 
according to the Weight of the horse (ie. 3—15 mg/kg/day, 
preferably 5—10 mg/kg/day), for from 20—40 days or longer 
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if required, but can be administered in the folloWing com 
mon dosage range: 1.5—10 grams of drug per day. HoWever, 
any EPM-effective dose or duration of treatment is Within 
the scope of the invention. Moreover, the dosage can be time 
release, Which can be any of the above, except that it is 
formulated so as to release a certain dose continuously or 
intermittently over a period of time. It is also a preferred 
embodiment to administer the drug as an injection, one or 
more times per day, at the same dose as above. 
Because diclaZuril has a relatively long plasma half-life in 
horses, it takes about 5—7 days of a standard 5 mg/kg/21 day 
treatment for the blood and cerebro-spinal ?uid concentra 
tions of diclaZuril to attain steady-state. The present inven 
tion includes a method to treat EPM Wherein steady-state is 
acheived by administering larger doses (“loading doses”) in 
the ?rst day or ?rst feW days of treatment. For example, it 
may be bene?cial to give 5—10 grams per day for the ?rst day 
or ?rst feW days to severely affected horses to attain steady 
state concentrations quicker than at loWer concentrations. 
Not all horses Will require such an accelerated treatment, 
although such treatment for all horses Would not be dam 
aging for those Who do not require it. 
The dosage for prophylaxis of EPM can be less than that 
necessary for treating EPM, but may be the same, depending 
on the need of the individual horse. A typical preventative 
dose of the triaZine-based anti-coccidials herein disclosed 
Would be 0.3—0.15 mg/kg/day, preferably 0.5—0.1 mg/kg/ 
day, hoWever, it can be administered via a feed formulation 
of 0.0002%—0.002% active ingredient, or 1 mg/kg'1 in feed 
or 200 g of 0.5% Clinacox pre-mix per ton of feed as Well. 
Horses can be fed formulations herein described on a 
schedule consistent With their needs. 
In summary, a full treatment plan for an animal With EPM 
Would comprise the folloWing sequential approaches: a.) 
reduce of the local in?ammatory response in the CNS; b.) 
kill the S. neurona in the CNS; and c.) provide nerve 
strengthening stimulus. In order to reduce the local in?am 
matory response, NSAID medication is effective; especially 
if started tWo days before the triaZine-based anti-coccidial is 
started. Banamine, phenylbutaZone or similar drugs seem to 
be optimal. In order to kill S. Neurona, 2.5 grams of 
diclaZuril per day for three Weeks seems to be suf?cient and 
may be optimal. In some severe cases, it may be appropriate 
to give higher doses initially, to increase the rate of steady 
state concentrations, or to give larger doses (ie. 2.5—7.5 
grams per day) for a longer period of time (ie. 1 to 2 Weeks). 
To optimiZe neuromuscular circuit function, exercise seems 
to speed recovery. Daily roundpen exercise and having the 
animal turned out as much as possible Will be bene?cial in 
most cases, so long as the animal tolerates it. Further either 
steroidal or non-steroidal anti-in?ammatory medication dur 
ing recovery may also be bene?cial. 
EXAMPLES 
Example 1 
The Disposition And Pharmacokinetics Of ToltraZuril. 
The folloWing Were initial studies to determine the bio 
availability of toltraZuril in non-EPM infected horses. Five 
horses Were given 5 grams/ 1000 lbs body Weight toltraZuril 
by stomach tube and blood levels Were determined at 
various time periods after administration. 
ToltraZuril Was very Well-absorbed after administration, 
With peak plasma concentrations occurring at 24 hours after 
drug administration. Additionally, this agent Was shoWn to 
have a long plasma half-life (54 hours). The long plasma half 
life facilitated maintainenance of plasma concentrations at 
consistently high (ug/ml) concentrations for Weeks. Under 
5,883,095 
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these conditions of continuous high plasma concentrations, 
the opportunity for the drug to enter the CNS Was maxi 
miZed. Pharmacokinetic projections based on these kinetics 
Were that single daily doses of 5 gms/horse Will yield plasma 
concentrations of about 30 pig/ml of toltraZuril after 15 days. 
Administered every second day, this same dose yields steady 
state plasma concentrations of about 15 pig/ml. 
Example 2 
This trial involved a 12 year old mare With a chronic 
relapsing case of EPM. This mare Was admitted to the Dept. 
of Clinical Medicine at a major Mid-Western University 
Teaching Hospital With an admitting diagnosis of severe 
neurologic dysfunction. The mare Was mildly depressed and 
“shaky”, With ataxia, severe proprioceptive de?cits and 
numerous super?cial bruises and abrasions. A cerebrospinal 
?uid analysis Was “positive” for antibodies to S. neurona. 
Based on the clinical symptoms, a presumptive diagnosis of 
EPM Was made. Treatment consisted of oral pyrimethamine 
(0.3 mg/kg, sid; Daraprim) and trimethoprimsulfamethox 
aZole (15 mg/kg, bid) and intravenous DMSO With ?uids for 
three days. 
The mare Was discharged With a diagnosis of EPM With 
presumptive secondary trauma at the second cervical verte 
bra. It Was recommended that treatment continue for 30 to 
60 days. Prior to discharge, the horse had great dif?culty 
Walking, and When exiting the stall she reared and fell on her 
poll. PhenylbutaZone Was prescribed, presumably for the 
local trauma and to reduce the in?ammatory response in the 
CNS. 
Ayear later, this horse Was shipped to Kentucky. She Was 
accepted as an experimental donation at the University of 
Kentucky. The mare Was sufficiently neurologically 
impaired so that she Was con?ned to a stall. She could not 
fend for herself at pasture With other horses, Was unable to 
graZe, could not Walk in a straight line, and Was rapidly 
losing condition. Later, the mare Was severely ataxic, very 
Weak and partially spastic, shoWing little ?exion of the 
hocks and difficulty in pivoting. This mare Was both serum 
and CSF “positive” for S. neurona on Western blot analysis 
at the time of donation to UK. FolloWing a neurological 
examination, the mare Was diagnosed as a classic severe, 
progressive case of EPM. The condition of the mare Was 
deteriorating and she Was considered a signi?cant challenge 
for any therapeutic agent. 
After 21 days of treatment With Clinacox (0.5% premix 
(5g/kg of feed (2.5 g/day)) Pharmacia & Upjohn Animal 
Health, 40 Centennial Road, Orangeville, Ontario, LDW 
3T3) there Was a marked amelioration of neurological signs 
and a concomitant improvement in physical condition. At 
the end of the treatment, the mare shoWed some neurologic 
regression, and the clinical condition Was not as good as 
earlier in the treatment. Treatment Was stopped 21 days after 
start due to lack of available Clinacox. Despite the partial 
regression in clinical signs in the later phases of therapy the 
condition of this mare has steadily improved since treatment 
ceased. 
Eighty-three days after the end of treatment, the mare Was 
clinically sound, active and fending for herself in pasture. 
Although some muscle atrophy and minor signs of perma 
nent neurologic damage remain, the mare has shoWn no sign 
of relapse since treatment ceased nine months ago. This 
mare hoWever, has not gone “CSF negative” for S. neurona, 
and When tested three months post treatment, she Was still 
CSF positive for antibodies to this agent Nevertheless, since 
treatment ceased, the clinical condition of this mare has 
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continued to improve and no clinical signs suggestive of 
relapse or re-infection With S. neurona have been observed. 
TWelve months after treatment ended, this mare Was 
returned to an experimental breeding herd on the UK farm, 
essentially neurologically normal. Additionally, this mare 
has not relapsed or re-infected, despite being in an infectious 
environment. Clinically, and effectively, this mare continues 
to improve and has shoWn no signs of relapse. At tWelve 
months post treatment, this mare is clinically sound and her 
most recent CSF tap suggest that the amount of anti- S. 
neurona antibody in her CSF is declining. This mare is likely 
to go CSF negative for S. neurona eventually. 
Example 3 
A four year old gelding Was treated for 3 Weeks With 
Clinacox as indicated in Example 2. The horse Was a grade 
3.5 neurological (on scale of 1—5, 5 most severe) When 
admitted, but had deteriorated prior to treatment Shortly 
after treatment started, he fell in his stall, could not get up, 
and had to be slung. He completed the three Weeks treatment 
at 2.5 g of diclaZuril/day as Clinacox and remained in the 
sling for several Weeks thereafter. At times, this horse Was so 
Weak that euthanasia Was seriously considered. HoWever, 
since treatment ended, he has improved dramatically, pre 
sumably due reduction in the in?ammatory response and to 
nerve regeneration once the organism Was eliminated. He 
Was turned out in a paddock, and Was last graded as 1.5 on 
the neurological scale. Six months after treatment ceased 
(July 1997) this gelding has continued to improve and has 
not relapsed. 
Example 4 
A fourteen year old mare, about grade 3, had relapsed on 
previously-knoWn therapies. She Was recently admitted, and 
given three Weeks diclaZuril, through Clinacox, as above. 
Her condition improved considerably during treatment and 
her post-treatment progress is being closely Watched. Five 
months after treatment ended this mare has not relapsed. 
Example 5 
A valuable tWo-year old colt in training Was admitted at 
grade 3 on the neurological scale. This horse Was unusual in 
that its symptoms included several cranial nerve signs, 
indicating that at least some of its EPM lesions Were in the 
brain. Prior to treatment, this animal had dif?culty ambu 
lating and leaned against the stall Wall; prognosis for this 
animal Was extremely guarded. This animal shoWed clear 
clinical improvement by the end of the ?rst Week of 
treatment, at Which time light round pen exercise Was 
started. At the end of the second Week, light exercise under 
a rider Was started. Administration of diclaZuril Was contin 
ued for a fourth Week in this animal because of its training 
schedule. 
Four months after therapy ceased, this animal has 
improved from grade 3 neurological (barely able to stand), 
to mild signs on one hind limb. This colt continues to 
improve daily and has shoWn no signs of relapse, and has 
returned to full training. 
Example 6 
Four 10,000 pound mares Were dosed With 500 g Clinacox 
(2.5 g diclaZuril) by stomach tube and plasma concentrations 
of the agent Were folloWed. Plasma concentrations of Cli 
nacox peak at about 1.0 pig/ml at 24 hours after dosing and 
decline With a half-life of about 45 hours. Pharmacokinetic 
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projections based on these data shoW that daily oral doses of 
ClinacoX should yield steady state plasma concentrations of 
diclaZuril by siX days after dosing and that trough plasma 
concentrations of diclaZuril are not less than 85% of peak 
plasma concentrations. 
These consistently high plasma concentrations of 
diclaZuril, the apparently high oral bioavailability of this 
agent and its apparently high lipid solubility makes it 
extremely likely that therapeutically signi?cant cerebrospi 
nal ?uid concentrations of this agent in animals are attained 
and maintained on the standard therapeutic schedule. 
More recently, CSF concentrations of 200—250 mg/ml 
diclaZuril in horses have been detected. These ?ndings of 
signi?cant steady state concentrations of diclaZuril in CSF 
support and eXtend the eXamples of oral bioavailability of 
these agents, their ability to penetrate the central nervous 
system and their apparent therapeutic efficacy in the treat 
ment of equine protoZoal myeloencephalitis. 
What is claimed is: 
1. A method to treat EPM in a horse is need of such 
treatment, comprising administering a pharmaceutically 
effective amount of a triaZine-based anti-coccidial. 
2. A method of claim 1, Wherein the triaZine-based 
anti-coccidial is chosen from the group consisting of 
claZuril, diclaZuril, toltraZuril and letraZuril. 
15 
10 
3. A method of claim 1, Wherein the triaZine-based 
anti-coccidial is toltraZuril. 
4. A method of claim 1, Wherein the triaZine-based 
anti-coccidial is diclaZuril. 
5. A method of claim 4, Which further comprises admin 
istering a pharmaceutically-effective anti-in?ammatory 
agent. 
6. A method of claim 5, Which further comprises eXercis 
ing the horse daily. 
7. A method to prevent S. neurona infection in horses 
comprising administering a prophylactic amount of a 
triaZine-based anticoccidial. 
8. A method of claim 7, Wherein the triaZine-based 
anticoccidial is chosen from the group consisting of claZuril, 
diclaZuril, toltraZuril and letraZuril. 
9. A method of claim 8, Wherein the triaZine-based 
anticoccidial is diclaZuril. 
10. A method to kill S. neurona in horses comprising 
administering S. neuronal-killing amount of diclaZuril. 
11. A horse-feed formulation useful to treat equine pro 
toZoal myeloencephalitis comprising a triaZine-based anti 
coccidial and an anti-protoZoal agent selected from the 
group consisting of: sulfonamide, trimethoprim and 
pyrimethamine. 
